PLRX
Pliant Therapeutics, Inc.
$1.11
-0.01 (-0.89%)
At close · Jul 16
Market Cap
$71.21M
Shares
61,920,249
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Bernard Coulie | CEO | $5,462,901 |
| Keith Cummings | CFO | $2,397,337 |
| Minnie Kuo | COO | $1,542,854 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Bernard Coulie | CEO | $6,614,704 |
| Keith Cummings | CFO | $3,099,874 |
| Hans Hull | Chief Business Officer | $2,015,324 |
| Mike Ouimette | Chief Legal and Compliance Officer and Secretary | $1,994,260 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Bernard Coulie | CEO | $11,165,999 |
| Keith Cummings | CFO | $4,438,908 |
| Hans Hull | Chief Business Officer | $4,357,277 |
| Mike Ouimette | Chief Legal and Compliance Officer and Secretary | $3,316,978 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Bernard Coulie | CEO | $10,927,715 |
| Keith Cummings | CFO | $3,443,354 |
| Hans Hull | Chief Business Officer | $3,154,751 |
| Mike Ouimette | Chief Legal and Compliance Officer and Secretary | $2,542,248 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Bernard Coulie | CEO | $5,221,353 |
| Keith Cummings | CFO | $1,883,743 |
| Hans Hull | Chief Business Officer | $1,653,630 |
| Barbara Howes | Former Chief Human Resource Officer | $995,913 |
| Mike Ouimette | General Counsel | $805,039 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Bernard Coulie | CEO | $2,391,822 |
| Hans Hull | Chief Business Officer | $839,867 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Bernard Coulie | CEO | $2,372,486 |
| Hans Hull | Chief Business Officer | $846,266 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Flavia Borellini, Ph.D. | Class II director | Appointed | 2026-07-13 |
| Robert Iannone, M.D., M.S.C.E. | Class I director | Appointed | 2026-07-13 |